A team of researchers at the University of Florida’s J. Crayton Pruitt Family Department of Biomedical Engineering is developing an innovative nanoparticle-based therapy for inflammatory bowel disease (IBD), a chronic condition affecting millions worldwide.
Jamal S. Lewis, Ph.D., associate professor of biomedical engineering, is leading a National Institutes of Health–funded project to engineer an immune-modulating therapy designed to restore balance in the gut. The project, titled “Commensal bacteria-derived nanoparticles for correcting gut inflammation,” focuses on leveraging biomaterial-based nanoparticles to address the underlying immune dysfunction that drives IBD.
Current treatments for IBD, including conventional drugs and biologics, can have significant side effects and often fail to provide durable, long-term relief. Lewis and his team aim to overcome these limitations by developing a more targeted and potentially safer therapeutic strategy rooted in naturally derived biomaterials.
Read more about UF Biomedical Engineering Professor Advances Novel Therapies for Inflammatory Bowel Disease With NIH Support.
